Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers

Stopped early · Not applicable

Conditions studied: Opioid-Related Disorders

In brief

Buprenorphine, a treatment for opioid dependence, can be mixed with another drug, naloxone, to limit abuse potential. Parenteral administration (intravenous or intramuscular injection) of buprenorphine/naloxone causes withdrawal symptoms in opioid dependent individuals. However, naloxone does not cause withdrawal symptoms in non-dependent opioid abusers. This study will investigate whether naloxone decreases the opioid agonist effect from injected buprenorphine, hence decreasing the abuse potential of buprenorphine/naloxone, in non-dependent opioid abusers.

Key facts

Study ID

NCT00134875

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

9

Starts

2000-12-01

Expected to finish

2017-12-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Non-dependent opioid abuser
• Actively abusing opioids by injection

You may not qualify if…

• Opioid dependence
• Signs or symptoms of opioid withdrawal, once admitted to residential unit

Where it is running

• Johns Hopkins University (BPRU) Bayview Campus — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.